Slide 1: Q2 2025 Financial Results
Q2 2025 Financial Results Conference call | July 24, 2025 www.materialise.com | NASDAQ: MTLS
Slide 2: Safe Harbor Summary
Safe Harbor Summary This presentatio n conta ins forwa rd-looking statements within the meaning of Sectio n 27A of the Securities Act of 1933, as amended, and Sectio n 21E of the Securities Excha nge Act of 1934, as amended, regar ding, among other things, our intentio ns, beliefs, assumptions, proj
Slide 3: Agenda
Agenda • Q2 2025 Business Highlights Brigitte de Vet-Veithen • Q2 2025 Financial Highlights CEO • Q2 2025 Financial Results • 2025 Financial Guidance Update • Q&A Koen Berges CFO 3
Slide 4: Q2 2025 - Business Highlights
Q2 2025 - Business Highlights Celebrating 35 years of Materialise Medical: Scaling up to reach more patients • Collaboration with J&J’s surgical business in EMEA to address the respiratory market • 510K clearance for Personalized Alignment features in our Surgicase Knee Planner Software and Manufact
Slide 5: Q2 2025 – Financial Highlights
Q2 2025 – Financial Highlights • Revenue of 64.8 mEUR, representing a decrease of 5.8% from Q2 2024 • Gross Profit of 37.8 mEUR, representing 58.3% of revenue • Adjusted EBIT of 3.1 mEUR, representing 4.7% of revenue • Net profit of 199 kEUR, representing 0 EUR-ct. per share • Reported Net Cash posi
Slide 6: Consolidated Revenue
Q2 2025 Consolidated Revenue Q2 2025 Revenue by Segment -5.8% 68,797 15% Software 64,831 Medical 34% Manufacturing 51% Q2 2024 Q2 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Revenue of 64.8 mEUR, representing a decrease of 5.8% compared to Q2 2024 • Consistent d
Slide 7: Consolidated Adjusted EBIT & EBITDA
Q2 2025 Consolidated Adjusted EBIT & EBITDA -9.8% 3,872 -21.0% 9,188 8,288 3,058 5.6% 13.4% 12.8% 4.7% Q2 2024 Adj. EBIT Q2 2025 Q2 2024 Adj. EBITDA Q2 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q2 2025 Adjusted EBIT decreased by 21% to 3.1 mEUR compared to Q2
Slide 8: Medical Segment
Q2 2025 Medical Segment +16.7% +30.8% 32,850 10,728 28,141 8,199 32.7% 29.1% Q2 2024 Revenue Q2 2025 Q2 2024 Adj. EBITDA Q2 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q2 2025 revenue increased 17% to 32.9 mEUR compared to Q2 2024 • Revenue from medical software
Slide 9: Software Segment
Q2 2025 Software Segment -0.1% -12.1% 11,226 1,374 1,373 9,872 12.2% 13.9% Q2 2024 Revenue Q2 2025 Q2 2024 Adj. EBITDA Q2 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q2 2025 revenue decreased by 12% to 9.9 mEUR compared to Q2 2024 • 84% recurring revenue generat
Slide 10: Manufacturing Segment
Q2 2025 Manufacturing Segment 29,429 -24.9% 2,416 22,109 8.2% -3.6% Q2 2024 Revenue Q2 2025 (807) Adj. EBITDA [Data in kEUR unless notes otherwise. All numbers and percentages rounded] Q2 2024 Q2 2025 • Compared to Q2 2024 segment revenue decreased by 25% to 22.1 mEUR • Further growth in strategic c
Slide 11: Income Statement Highlights
Income Statement Highlights Q2 2025 Q2 2024 Gross profit margin (in %) Revenue 64,831 68,797 58.3% Cost of sales (27,053) (29,570) 57.0% Gross profit 37,778 39,227 Research & development expenses (11,120) (11,090) Sales & marketing expenses (15,471) (15,636) Q2 2024 Q2 2025 General & administrative
Slide 12: Other Financial Highlights
Other Financial Highlights Balance Sheet items 06/30/25 12/31/24 Cash flow from operations 8,400 Cash and equivalents 116,712 102,304 Borrowings 53,667 41,284 Net Cash 63,045 61,020 -27 Trade receivables 49,564 53,052 Q2 2024 Q2 2025 Inventories 14,678 16,992 Capital expenditures (cash impact) Trade
Slide 13: 2025 Financial Guidance Update
2025 Financial Guidance Update Prudent outlook on market condition in H2 leading to slightly reduced revenue guidance while maintaining prior Adjusted EBIT guidance • Expect 2025 consolidated revenue within 265 - 280 mEUR range • Expect 2025 consolidated Adjusted EBIT within 6 - 10 mEUR range 13
Slide 14: Adjusted EBIT/EBITDA Reconciliation
Appendix Adjusted EBIT/EBITDA Reconciliation [Data in kEUR unless noted otherwise. All numbers and percentages rounded] Q2 2025 Q2 2024 Net profit/(loss) 199 3,875 Income taxes (521) 959 Financial expenses 4,039 1,441 Financial income (987) (2,474) EBIT 2,730 3,801 Depreciation & amortization 5,230
Slide 15: Thank You
Thank You Contact: Investor Relations Materialise investors@materialise.com 15